Antibody–drug conjugates (ADCs)—new targeted therapies

By Papakonstantinou Georgios  

memo - Magazine of European Medical Oncology, Vol. 6, Iss. 4, 2013-12 ,pp. : 223-224

Springer Publishing Company

Access to resources Recommend Favorite

Advances in the Development of Site-Specific Antibody-Drug Conjugation

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 15, Iss. 7, 2015-01 ,pp. : 828-836

Bentham Science Publishers

Access to resources Recommend Favorite

Antibody–drug conjugates for the treatment of B-cell non-Hodgkin’s lymphoma and leukemia

By Chu Yu-Waye   Polson Andrew  

Future Oncology, Vol. 9, Iss. 3, 2013-03 ,pp. : 355-368

Future Medicine

Access to resources Recommend Favorite

Antibody–cytotoxic drug conjugates in clinical trials and future perspectives: the development of Trojan horses

By Tryfonopoulos Dimitrios  

memo - Magazine of European Medical Oncology, Vol. 7, Iss. 1, 2014-02 ,pp. : 47-49

Springer Publishing Company

Access to resources Recommend Favorite

Orexin 2 receptor as a potential target for immunotoxin and antibody-drug conjugate cancer therapy

By                

Oncology Letters, Vol. 3, Iss. 3, 2012-01 ,pp. : 525-529

Spandidos Publications

Access to resources Recommend Favorite